Cachexia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 16 Jun 2026 04:02:33 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cachexia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Visugromab Compared to Placebo in Patients with Cancer-Related Cachexia to Test How Well It Works and How Safe It Is https://clinicaltrials.eu/trial/a-study-of-visugromab-compared-to-placebo-in-patients-with-cancer-related-cachexia-to-test-how-well-it-works-and-how-safe-it-is/ Thu, 30 Apr 2026 13:08:39 +0000 https://clinicaltrials.eu/trial/a-study-of-visugromab-compared-to-placebo-in-patients-with-cancer-related-cachexia-to-test-how-well-it-works-and-how-safe-it-is/ This study is looking at cancer-associated cachexia, which is a condition where people with cancer experience significant weight loss and muscle wasting that cannot be reversed simply by eating more food. This condition can cause loss of appetite, weakness, and reduced quality of life in people with advanced cancer. The study will test a medication called Visugromab, also known by its code name CTL-002, which is given as an infusion into a vein. Some participants will receive Visugromab while others will receive placebo. The purpose of the study is to investigate how well Visugromab works in people with cancer-associated cachexia and to assess its safety.

During the study, participants will receive treatment for up to 12 months. The researchers will measure several things to see if the treatment is helping, including changes in body weight and appetite over a 12-week period. Body weight will be tracked from the beginning of the study, and appetite will be measured using a questionnaire that asks specific questions about eating and food-related concerns. The study will also look at muscle mass using imaging scans such as CT or MRI, which are types of medical imaging that create detailed pictures of the inside of the body. Physical function will be tested through simple exercises like a chair stand test, and daily physical activity levels will be monitored.

Throughout the study, doctors will carefully monitor participants for any side effects or unwanted reactions to the treatment. Participants will also complete questionnaires about their quality of life, how severe their symptoms are, and whether they notice any changes in their condition. Blood samples will be taken to measure the levels of the medication in the body. The study will track overall health outcomes and how the cancer responds to ongoing treatment during this time.

]]> Study of NGM120 in patients with colorectal cancer and cancer cachexia: Evaluating effects on body weight https://clinicaltrials.eu/trial/study-of-ngm120-in-patients-with-colorectal-cancer-and-cancer-cachexia-evaluating-effects-on-body-weight/ Thu, 30 Apr 2026 13:08:11 +0000 https://clinicaltrials.eu/trial/study-of-ngm120-in-patients-with-colorectal-cancer-and-cancer-cachexia-evaluating-effects-on-body-weight/ This study focuses on patients with colorectal cancer who have developed a condition called cancer cachexia, which is characterized by significant unintentional weight loss and muscle wasting. The study will test a new medication called NGM120, which is a type of humanized monoclonal antibody (a laboratory-created protein that targets specific cells in the body), comparing it with a placebo. The main purpose is to determine if NGM120 can help manage body weight in people with cancer cachexia.

The treatment will be given as an subcutaneous injection (an injection under the skin). The medication or placebo will be administered over several weeks, with participants being monitored for a total of 16 weeks. The maximum daily dose of NGM120 will be 200 milligrams, with a total maximum dose of 2000 milligrams over the course of treatment.

Throughout the study, participants will be evaluated for changes in their body weight and overall health status. The study will also look at how well the body tolerates NGM120 and track any side effects that may occur. Various aspects of participants’ well-being will be monitored, including their fatigue levels, physical function, appetite, and ability to perform daily activities.

]]> A Study of Ponsegromab Combined with Chemotherapy for Adults with Pancreatic Cancer that has Spread and Caused Weight Loss https://clinicaltrials.eu/trial/a-study-of-ponsegromab-combined-with-chemotherapy-for-adults-with-pancreatic-cancer-that-has-spread-and-caused-weight-loss/ Wed, 29 Apr 2026 15:08:50 +0000 https://clinicaltrials.eu/trial/a-study-of-ponsegromab-combined-with-chemotherapy-for-adults-with-pancreatic-cancer-that-has-spread-and-caused-weight-loss/ This study is looking at a condition called cancer cachexia in people who have metastatic pancreatic ductal adenocarcinoma, which is a type of cancer that starts in the pancreas and has spread to other parts of the body. Cancer cachexia means significant body weight loss, loss of muscle, and tiredness that can happen in people with cancer. The study will test a medicine called ponsegromab, which is also known by its code name PF-06946860. This medicine is a type of antibody that works against a protein in the body called GDF15. Some people in the study will receive ponsegromab while others will receive placebo, and all participants will also continue to receive their regular chemotherapy treatment with either nab-paclitaxel and gemcitabine or FOLFIRINOX.

The purpose of the study is to find out if ponsegromab can help people gain body weight, improve appetite-related symptoms, and see if it is safe to use. During the study, participants will receive either ponsegromab or placebo along with their regular chemotherapy treatment. The study will measure changes in body weight, appetite symptoms, physical activity levels, and body composition using CT scan or MRI imaging. The study will also look at how the cancer responds to treatment and track overall survival and quality of life measures. Participants will be monitored for side effects and any changes in their health throughout the study period.

The study will last for several years and includes regular visits where measurements will be taken at different time points, with an important assessment at week 12. The study also includes an open-label extension phase where participants may continue to receive ponsegromab. Throughout the study, doctors will check body weight, muscle mass, fat tissue, physical activity, fatigue levels, and overall well-being using questionnaires and physical measurements.

]]> Study of ponsegromab for patients with cancer cachexia and elevated GDF-15 levels https://clinicaltrials.eu/trial/study-on-the-effects-of-ponsegromab-for-patients-with-cancer-related-weight-loss-and-high-gdf-15-levels/ Wed, 29 Apr 2026 14:30:35 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ponsegromab-for-patients-with-cancer-related-weight-loss-and-high-gdf-15-levels/ This study focuses on cancer cachexia, a condition where cancer patients experience significant weight loss and muscle wasting. The research evaluates a new medication called ponsegromab, which is being tested in patients who have non-small cell lung cancer, pancreatic cancer, or colorectal cancer along with cachexia. These patients must also have elevated levels of a substance called GDF-15 in their blood.

The study aims to determine if ponsegromab can help patients maintain or regain body weight compared to placebo. The medication is given as a subcutaneous injection, which means it is administered under the skin. The treatment period lasts for 12 months, during which patients receive either ponsegromab or a placebo.

During the study, researchers will monitor changes in body weight and physical activity. They will also track how well patients can move around and perform daily activities. The study includes the use of special sensors that measure movement and walking speed. Patients will also be asked about their appetite, feelings of nausea, and energy levels. Throughout the study, doctors will closely monitor the safety of the treatment by checking for any side effects.

]]>